Board of Directors


Chairman & Co-Founder


Dr. Javitt has played leadership roles in seven successful healthcare IT and biopharma startups with public exits. He has additionally led drug-development engagements for Merck, Allergan, Pharmacia, Novartis, and Pfizer. He was appointed to healthcare leadership roles under Presidents Reagan, George H.W. Bush, Clinton, and George W. Bush. In the latter role he was commissioned to lead the White House policy for universal adoption of Health IT and establishment of the Office of the National Coordinator. He is a graduate of Princeton University, Cornell University Medical College, Harvard School of Public Health, the Wills Eye Hospital, and Johns Hopkins Medical School. Dr. Javitt has published more than 200 scientific works in the areas of health outcomes and pharmacoeconomics that have been cited by more than 16,000 people.






Mr. Chaim Hurvitz has been the Chief Executive Officer of CH Health since May 2011. He previously served as the President of Teva International Group at Teva Pharmaceutical Industries Ltd from April 2002 to 2010 was a Director and member of the senior management of Teva Pharmaceuticals Industries Ltd. He serves as the Chairman of Galmed Pharmaceuticals Ltd. and has been its Director since 2011. He has been a Director of TheraCoat Ltd. since October 2010. He is a member of the management of the Manufacturers Association of Israel and head of its pharmaceutical branch. Mr. Hurvitz holds a Bachelor of Arts degree in political science and economics from Tel Aviv University, which was awarded in 1985.


Co-founder and Chair, Scientific Advisory Board


Professor Javitt has devoted the past 30 years to the intersection of psychiatry and brain science. He was the first to identify the role of the NMDA receptor in modulating human thought processes in psycho-affective disorders. He is the author of more than 250 scientific publications and 10 patents in the field and is one of the most-widely cited authors in neuro-psychiatry. His work has merited awards from the American Psychiatric Association and other leading organizations.



Audit Committee Chair


Mr. Flynn is a founding investor in NeuroRx. He is an entrepreneur with more than 30 years of senior executive experience. He has provided leadership to numerous successful organizations and has served in a variety of roles, including CEO, COO, CFO and advisor.  Pat currently serves as COO of Good Measures, Inc.  He co-founded Predilytics, Inc., which was sold to Welltock, Inc.  Previously, Pat served as COO and then as CEO of Health Dialog, which was sold to BUPA International. Pat continued with BUPA, opening their business in the GCC and China.  Mr. Flynn began his career with Bank of America where he held several positions over the course of 15 years, including Vice President of World Banking and Vice President of Risk Management.



Dr. Glied, whose principal areas of research are in health policy reform and mental health care policy, was named Dean of New York University’s Robert F. Wagner Graduate School of Public Service in 2013.  From 1989-2013, Dr. Glied was professor of health policy and management at Columbia University’s Mailman School of Public Health and served as chair of the department of health policy and management from 1998-2009.  In 2010, Dr. Glied was confirmed by the U.S. Senate as Assistant Secretary for Planning and Evaluation at the Department of Health and Human Services, serving in that capacity from July 2010 through August 2012. She had previously served as senior economist for health care and labor market policy on the President’s Council of Economic Advisers in 1992-1993, under Presidents Bush and Clinton, and participated in the Clinton Health Care Task Force.



© 2016 NeuroRx, Inc.

*These drugs are investigational and not approved by the US FDA




Aaron Gorovitz is a partner of Lowndes, Drosdick, Doster, Kantor, and Reed, of Orlando, FL. He is a graduate of Muhlenberg College and the George Washington University School of Law. In addition to his 25 years of legal experience in complex commercial transactions, he has considerable involvement in early stage biotechnology and health information technology companies.